Trial Profile
Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Abbott Biologicals BV
- 06 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2010 New trial record